Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biotechnology company focused on targeted protein degradation (TPD). Through these filings, investors can review how Kymera reports its clinical progress, collaboration agreements, financing activities and corporate governance matters.
Kymera’s current reports on Form 8-K disclose material events such as clinical data presentations for KT-621, an investigational first-in-class oral STAT6 degrader in atopic dermatitis and asthma, and updates on KT-579, an oral IRF5 degrader for immune-mediated diseases. 8-K filings also describe key collaboration developments, including the IRAK4 degrader KT-485/SAR447971 with Sanofi for immuno-inflammatory diseases and an exclusive option and license agreement with Gilead Sciences covering an oral CDK2 molecular glue degrader program for potential use in breast cancer and other solid tumors.
Filings related to public offerings and capital structure outline Kymera’s underwritten offerings of common stock and pre-funded warrants, shelf registration statements on Form S-3 and associated underwriting agreements and registration rights agreements. These documents explain how the company raises capital to advance its pipeline of preclinical and clinical degrader programs and may detail potential milestone and royalty structures under collaboration arrangements.
Users can also consult SEC filings for information on Nasdaq listing details, including the KYMR ticker on The Nasdaq Global Market, as well as shareholder meeting results, board composition and executive transitions. Stock Titan’s platform pairs these filings with AI-powered summaries that highlight key terms, material developments and financial implications, helping readers navigate complex documents such as 8-Ks, registration statements and related exhibits more efficiently.
Kymera Therapeutics insider transactions by CEO and director Nello Mainolfi on 09/16/2025: The filing shows the exercise of a fully vested stock option with a $2.08 exercise price that converted into 30,000 shares, and an offsetting sale of 30,000 shares at $49. Following these transactions the reporting person beneficially owned 660,482 shares.
The filing notes these trades were executed under a Rule 10b5-1 trading plan adopted September 6, 2024, and the derivative shares underlying the option are fully vested and exercisable with an expiration date of November 13, 2029.
Kymera Therapeutics (KYMR) Form 144 notice reports a proposed sale of 30,000 common shares. The shares are scheduled to be sold through UBS Financial Services on NASDAQ on 09/16/2025 with an aggregate market value of $1,470,000. The filing states 71,497,597 shares outstanding. The 30,000 shares were acquired on 09/16/2025 by exercise of stock options from the issuer and payment was in cash on the same date. The filer reports no securities sold in the past three months and affirms no undisclosed material adverse information.
Kymera Therapeutics insider grant to Chief Legal Officer The filing shows that Brian Adams, Chief Legal Officer of Kymera Therapeutics (KYMR), was granted 52,500 restricted stock units (RSUs) and a stock option covering 105,000 shares on September 3, 2025. The RSUs vest in four equal annual installments beginning September 3, 2026, subject to continued employment. The option has an exercise price of $43.30, vests 25% on September 3, 2026, with the remainder in 36 equal monthly installments, and expires on September 2, 2035. Following the grants, Mr. Adams directly beneficially owns 52,500 shares from the RSUs and 105,000 option shares reported.
Brian Adams, identified as a Director and Chief Legal Officer, submitted an Initial Statement on Form 3 for Kymera Therapeutics, Inc. (KYMR) reporting the event date 09/03/2025. The filing states that no securities are beneficially owned by the reporting person at the time of this statement. The form is signed by an attorney-in-fact, Bruce Jacobs, and includes an exhibit listing a Power of Attorney. This filing notifies the market of the officer/director's initial Section 16 status while showing there is currently no direct or indirect ownership to disclose.
Kymera Therapeutics, Inc. announced that Chief Legal Officer Ellen Chiniara, J.D. informed the company on August 27, 2025 of her intent to retire from the role, effective September 3, 2025. The company states that her retirement is not due to any disagreement regarding operations, policies, or practices, and she will not receive severance payments or benefits in connection with her departure.
Effective September 3, 2025, Brian R. Adams, J.D. will succeed Ms. Chiniara as Chief Legal Officer. The company also issued a press release on September 3, 2025 announcing the retirement and appointment, which is furnished as an exhibit to this report.
Kymera Therapeutics, Inc. (KYMR) is reported as having significant institutional ownership by Wellington Management and affiliated entities. The filing shows an aggregate beneficial ownership of 5,372,061 shares, representing approximately 7.66% of the outstanding common stock. The reporting parties state they have no sole voting or dispositive power and instead hold shared voting power of 4,872,818 shares and shared dispositive power of 5,372,061 shares. The securities are owned of record by clients of Wellington investment advisers and the filing is submitted on Schedule 13G, with a certification that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control.
Kymera Therapeutics (KYMR) reported Q2 2025 interim results showing strong liquidity while continuing to invest heavily in R&D. The company held $963.1 million of combined cash, cash equivalents and marketable securities at June 30, 2025 and completed a June follow-on that generated aggregate gross proceeds of approximately $288.4 million.
Collaboration revenue totaled $11.5 million for the quarter and $33.6 million for the six months, mainly from the Sanofi collaboration; Kymera also received a $40.0 million upfront payment under an option agreement with Gilead. R&D expense rose to $158.6 million for the six months, contributing to a six-month net loss of $142.2 million and an accumulated deficit of $896.8 million.
Kymera Therapeutics announced that it reported its financial results for the quarter ended June 30, 2025 and furnished the related press release as Exhibit 99.1 to a Current Report on Form 8-K. The filing states the press release is being furnished and not deemed "filed" under the Exchange Act, and the cover page includes interactive data.
The Form 8-K text does not include the underlying financial figures; readers are referred to the furnished press release for detailed results. The report is signed by Nello Mainolfi, Ph.D., President and Chief Executive Officer, confirming the submission of the exhibit.
Baker Bros. Advisors LP and affiliates have filed Amendment No. 2 to Schedule 13D disclosing a 9.5% beneficial stake in Kymera Therapeutics, Inc. (KYMR). The group – Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, and principals Julian C. Baker and Felix J. Baker – now control 6,666,540 shares of common stock, based on 70,157,214 shares outstanding as of 30 Jun 2025.
Recent transaction. On 26 Jun 2025 Kymera priced a public offering of 5,044,500 shares at $44.00 and 655,500 prefunded warrants at $43.9999. Funds managed by Baker Bros. purchased 655,500 common shares and 655,500 prefunded warrants (split 55,191/600,309 between 667 LP and Life Sciences LP). The offering closed 30 Jun 2025.
- Voting / dispositive power: Sole voting and dispositive power over all 6.67 M shares.
- Prefunded warrants: 1-for-1 conversion at $0.0001, exercisable indefinitely but capped at a 4.99% ownership limit (adjustable up to 19.99% with 61 days’ notice).
- Registration rights: Funds obtained shelf and underwritten offering rights (up to three offerings over ten years) effective from 28 Feb 2026.
- Director lock-up: Felix Baker agreed not to sell KYMR securities until 24 Sep 2025 (subject to customary exceptions).
The filing emphasises that the position is investment-motivated; the funds may buy or sell additional securities depending on prevailing conditions, and no plans for extraordinary corporate actions are currently disclosed.
FAQ
What is the current stock price of Kymera Therapeutics (KYMR)?
What is the market cap of Kymera Therapeutics (KYMR)?
